Q2 2018 EPS Estimates for Becton Dickinson and Co Decreased by Jefferies Group (BDX)
Becton Dickinson and Co (NYSE:BDX) – Analysts at Jefferies Group cut their Q2 2018 EPS estimates for Becton Dickinson and in a research report issued on Tuesday. Jefferies Group analyst B. Couillard now forecasts that the medical instruments supplier will earn $2.56 per share for the quarter, down from their previous forecast of $2.60. Jefferies Group also issued estimates for Becton Dickinson and’s Q3 2018 earnings at $2.81 EPS, Q1 2019 earnings at $3.05 EPS, Q3 2019 earnings at $3.22 EPS and Q4 2019 earnings at $3.33 EPS.
A number of other research analysts have also weighed in on the company. Morgan Stanley increased their price objective on Becton Dickinson and from $245.00 to $250.00 and gave the company an “equal weight” rating in a report on Wednesday. Piper Jaffray Companies reissued an “overweight” rating and issued a $260.00 price objective (up from $223.00) on shares of Becton Dickinson and in a report on Tuesday, February 6th. Zacks Investment Research raised Becton Dickinson and from a “hold” rating to a “buy” rating and set a $259.00 price objective on the stock in a report on Friday, January 19th. Bank of America reissued a “buy” rating and issued a $260.00 price objective on shares of Becton Dickinson and in a report on Friday, January 19th. Finally, Citigroup raised Becton Dickinson and from a “sell” rating to a “neutral” rating in a report on Friday, January 5th. Four analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Becton Dickinson and currently has an average rating of “Buy” and a consensus price target of $237.27.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, beating analysts’ consensus estimates of $2.41 by $0.07. The business had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The company’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the company earned $2.33 earnings per share.
A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. grew its holdings in Becton Dickinson and by 6.0% during the fourth quarter. BlackRock Inc. now owns 18,811,302 shares of the medical instruments supplier’s stock worth $4,026,750,000 after acquiring an additional 1,071,288 shares during the period. Vanguard Group Inc. grew its holdings in Becton Dickinson and by 8.5% during the second quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock worth $3,366,809,000 after acquiring an additional 1,353,780 shares during the period. State Street Corp grew its holdings in Becton Dickinson and by 3.5% during the second quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock worth $2,003,834,000 after acquiring an additional 342,873 shares during the period. Northern Trust Corp grew its holdings in Becton Dickinson and by 4.0% during the second quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock worth $549,028,000 after acquiring an additional 106,966 shares during the period. Finally, Fundsmith LLP grew its holdings in Becton Dickinson and by 0.3% during the second quarter. Fundsmith LLP now owns 2,302,590 shares of the medical instruments supplier’s stock worth $449,258,000 after acquiring an additional 5,977 shares during the period. 75.68% of the stock is currently owned by hedge funds and other institutional investors.
The business also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Investors of record on Friday, March 9th will be issued a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a yield of 1.38%. The ex-dividend date is Thursday, March 8th. Becton Dickinson and’s dividend payout ratio (DPR) is 229.01%.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.